



Fate Therapeutics, Inc.
Investor Relations Department
3535 General Atomics Ct.
Suite 200
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FATE

Last Trade:	4.21
Trade Time:	4:00 PM ET Sep 19, 2017
Change:	-0.04 (-0.941%)
Day Range	4.11 - 4.40
52-Week Range	1.80 - 5.68
Volume	177,448

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 18, 2017
[Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease](#)

Sep 14, 2017
[Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development](#)

Sep 1, 2017
[Fate Therapeutics to Present at Upcoming Investor Conferences](#)

Aug 16, 2017
[Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy](#)

Aug 14, 2017
[Fate Therapeutics Reports Second Quarter 2017 Financial Results](#)

Upcoming Events [\[View all \]](#)

Sep 26, 2017 10:20 AM ET
[Cantor Fitzgerald Global Healthcare Conference](#)

Sep 28, 2017 10:00 AM ET
[Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 16, 2017
[Annual Report \(10-K\)](#)

Mar 22, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 14, 2017
[Quarterly Report \(10-Q\)](#)

May 15, 2017
[Quarterly Report \(10-Q\)](#)

Nov 7, 2016
[Quarterly Report \(10-Q\)](#)